Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

29th August 2016 – Oncology Venture – First metastatic breast cancer patient with LiPlaCis™ confirmed partial response

Oncology Venture has announced that the first patient with metastatic breast cancer included in its LiPlaCis™ extension – proof of concept trial has obtained a confirmed Partial Remission (ie >30% tumour reduction) (press release link). The patient is the first of 12-15 patients whose tumour tissue has been pre-screened as a highly likely responder by Oncology Venture’s Drug Response Predictor (DRP™). Bio-Link is seeking partners to co-develop or secure rights to LiPlaCis™. Click here for full press release.

oncology venture logo-1

28th July 2016 – “Realising Value from Biotechnology” – Bio-Link Published in Australasian Biotechnology

Bio-Link Executive Directors Christopher Boyer and Dr Christian Toouli have written an article for the recently published July addition of “Australasian Biotechnology” (volume 26, number 2). The article focuses on the need for biotechnology innovators to prioritise commercialisation, and in particular partnering, to realise maximum value from their assets. Please click here to read the article.

25th July 2016 – Bio-Link Australia to Offer Patsnap Global Patent Database and IP Analytics Software

Bio-Link has secured a license to PatSnap’s Global Patent Database and IP Analytics Software, enabling Bio-Link to offer a tailored patent analytics service to its biopharmaceutical, medical device and academic clients. Click here for full press release.

Patsnap IP

24th December 2015 – Bio-Link Engaged by Oncology Venture

Bio-Link has been engaged by Oncology Venture to partner its clinical stage precision oncology drug candidates,

  • Irofulven – a phase II/III cytotoxic drug candidate under development together with a companion diagnostic technology (Irofulven DRP®) to identify patients highly likely to respond to therapy. Oncology Venture will soon commence a focused phase II trial of irofulven in highly likely patient responders with castration-resistant prostate cancer.
  • APO010 – a phase II-ready, highly potent Fas / CD95 / Apo1 agonist which mimics cytotoxic T-lymphocyte signalling to induce cancer cell apoptosis together with an immuno-companion diagnostic technology (APO010 DRP®) to identify patients highly likely to respond to therapy. Oncology Venture will soon commence phase II clinical studies in highly likely patient responders in metastatic breast cancer and multiple myeloma.

To read more about these partnering opportunities, please click here.

Oncology Venture

December 11th – CMRI awarded A$10mil grant from the ACRF

The Children’s Medical Research Institute has won a record-breaking A$10 million grant from the Australian Cancer Research Foundation. The A$10 million grant is one of the largest grants for medical research equipment in Australian history and will be used to establish The ACRF International Centre for the Proteome of Cancer (ProCan) at the Children’s Medical Institute in Westmead. The centre will be working to analyse tens of thousands of samples of cancer for precise protein levels in small biopsies. In phase two of the project, advanced computer analysis will compare the protein data with already available data for each cancer, providing a major step forward for cancer diagnosis and treatment. For more information, please see the press release.